key: cord-0742201-cj9tuftf
authors: Taylor, Richard S.
title: Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
date: 2021-04-12
journal: CMAJ
DOI: 10.1503/cmaj.78240
sha: 6085abe6dd4319d93f0d6339f3a302fe5b2345cd
doc_id: 742201
cord_uid: cj9tuftf

nan

Across Canada, both influenza and respira tory syncytial virus (RSV) have been almost completely absent during the 2020/21 win ter. 1 Data from the Southern hemisphere showed the same phenomenon following the implementation of public health meas ures for coronavirus disease 2019 (COVID 19). 2 Despite the low incidence of RSV, pro grams across Canada have continued to promote the administration of palivizumab (PVZ) prophylaxis to eligible infants at a cost of about $1500 per dose. Canadian taxpayers are currently on track to spend nearly $50 million on a drug 3 unlikely to have any benefit this winter.

In 2017, Mitchell and Peiris 4 correctly pointed out that the social determinants of health need to be addressed when con sidering the effectiveness of PVZ prophy laxis for infants in the Artic with RSV. 5 If they have not already done so, all Canad ian PVZ programs need to immediately stop prophylaxis. Prophylaxis guidelines should be reviewed, with a switch to a flexible response to RSV activity. Palivi zumab is an antibody, so unlike a vaccine, it becomes effective within hours of injec tion. Its administration can surely wait until there is significant risk of community acquired RSV.

What will happen when COVID19 rules are lifted? Will it become a societal norm to wash hands, wear a mask in crowded places, use hand sanitizer and avoid school or work for upper respiratory tract infections? We do not yet know. In Austra lia, there have been recent summer spikes in RSV activity, 6 possibly related to a reduction in social distancing. Now that we have rediscovered a far more effective approach to infant hospital respiratory admissions, it would be foolish to assume that life will quickly return to normal. Pro phylaxis programs for RSV will need to adjust to the new reality. 

Respiratory virus detections in Canada. Ottawa: Government of Canada

The impact of COVID19 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian win ter

Provinces spent $43M on preemie drug experts say can be made for a fraction of the cost

Reducing the burden of lower respiratory tract infections in infants in the Can adian Arctic

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy fullterm <6monthold infants from the circumpolar region of Nunavik

Sharp rise in RSV infections among children has experts warning parents not to relax COVID19 social distancing measures

Competing interests: Richard Taylor was chair of the British Columbia Respiratory Syncytial Virus Immunoprophylaxis Committee.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BYNCND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/ licenses/byncnd/4.0/